Even when encountered with OX40 agonist, potential immunotherapy that enhances anti-tumor immune responses, it did not harm the regulatory ability of Tregs due to the simultaneous increase in granzyme B, IFN-γ, and T-bet expression. Here, GZMB is linked to neoplasm.